Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$3.23 ▲ +0.03
(+0.94%)
MKT CAP: $293.9M • VOL: 458.3K
52W L $2 52W H $5
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$3
MEDIAN
$4
MEAN
$4
HIGH
$4
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE SABS TAPE
SABS // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $3.91 | $3.71 | 2025-02-14 | $2.94 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $4.07 | $3.81 | 2025-02-06 | $3.04 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $3.68 | $3.55 | 2025-01-29 | $3.10 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $3.29 | — | 2025-01-17 | $3.17 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $2.84 | $3.07 | 2025-01-09 | $2.87 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $3.84 | $3.36 | 2024-12-18 | $2.81 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $3.13 | $3.26 | 2024-12-04 | $3.00 | -4.3% | 48% | C |